Oncovita signs exclusive licensing agreement with Institut Pasteur
Oncovita, a biotech company dedicated to the development of life-saving new treatments, in particular anti-cancer therapies, announces today that it has entered into a licensing agreement with Institut Pasteur, granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform.